Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find out which is a better treatment for diabetic macular
edema (DME): laser alone, laser combined with an intravitreal injection of triamcinolone,
laser combined with an intravitreal injection of ranibizumab, or intravitreal injection of
ranibizumab alone. At the present time, it is not known whether intravitreal steroid or
anti-vascular endothelial growth factor (anti-VEGF) injections, with or without laser
treatment, are better than just laser by itself. It is possible that one or both of the types
of injections, with or without laser treatment, will improve vision more often than will
laser without injections. However, even if better vision outcomes are seen with injections,
side effects may be more of a problem with the injections than with laser. Therefore, this
study is conducted to find out whether the benefits of the injections will outweigh the
risks.
Phase:
Phase 3
Details
Lead Sponsor:
Jaeb Center for Health Research
Collaborators:
Allergan Genentech, Inc. National Eye Institute (NEI)